# US 2018/0023146 A1 · 3.beta-hydroxysteroid dehydrogenase in steroid dependent disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023146 A1
- Document ID: US20180023146A1
- Status: Published application
- Kind: A1
- Application number: 15/712,509
- Filed: 2017-09-22
- Published: 2018-01-25
- Earliest claimed: 2013-07-15
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Nima Sharifi; Kai-Hsiung Chang
- Web page: https://patentgrep.com/patent/US20180023146A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/57555: of the prostate
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/904: acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and kits for characterizing a subject having a steroid-dependent disease such as prostate cancer are described. A method of treating a steroid-dependent disease in a subject by obtaining a biological sample from the subject, determining if the HSD3B1(1245C) gene or 3βHSD1(367T) protein is expressed in the biological sample, and providing treatment other than or in addition to steroid ablation to the subject if the HSD3B1(1245C) gene or 3βHSD1(367T) protein is expressed is also described.

## Claims

### Claim 1

A method of treating a steroid-dependent disease in a subject in need thereof, comprising:
determining that a cytosine nucleotide is present at position 1245 of the HSD3B1 gene or a threonine is present at position 367 of the 3bHSD1 protein by assaying a biological sample from the subject, and
administering treatment to the subject selected from the group consisting of salvage cryotherapy, radiation therapy, radical prostatectomy, proton therapy, and high intensity focused ultrasound, or continuing steroid ablation together with administration of an androgen receptor antagonist, administration of an androgen synthesis inhibitor, or administration of a 3βHSD1 inhibitor to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the steroid-dependent disease is cancer and the biological sample is a cancer cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cancer is prostate cancer.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The method of claim 3, wherein treatment is selected from the group consisting of salvage cryotherapy, radiation therapy, radical prostatectomy, proton therapy, and high intensity focused ultrasound.

### Claim 6

(canceled)

### Claim 7 (depends on 3)

The method of claim 3, wherein treatment comprises continuing steroid ablation together with administration of an androgen receptor antagonist, administration of an androgen synthesis inhibitor, or administration of a 3βHSD1 inhibitor to the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the treatment is administration of abiraterone or enzalutamide.

### Claim 9 (depends on 1)

The method of claim 1, wherein the presence of 3βHSD1 (367T) protein is determined.

### Claim 10 (depends on 9)

The method of claim 9, wherein the presence of the 3βHSD1 (367T) protein is determined using an immunoassay.

### Claim 11 (depends on 1)

The method of claim 1, wherein the presence of the HSD3B1(1245C) allele is determined.

### Claim 12 (depends on 11)

The method of claim 11, wherein the presence of the HSD3B1(1245C) allele is determined using PCR methods, sequencing methods, RFLP, or SNP Chip technology.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 14

A kit for guiding treatment of steroid-dependent disease in a subject comprising:
one or more primers or probes capable of detecting 3βHSD1 (367T) or HSD3B1(1245C), and a package for holding the primers or probes.

### Claim 15 (depends on 14)

The kit of claim 14, wherein the kit further comprises instructions for using the kit to carry out a method of guiding treatment of steroid-dependent disease in a subject.

### Claim 16 (depends on 14)

The kit of claim 14, wherein the kit includes a probe capable of detecting 3βHSD1 (367T).

### Claim 17 (depends on 16)

The kit of claim 16, wherein the probe is an antibody.

### Claim 18 (depends on 14)

The kit of claim 14, wherein the kit includes a primer capable of detecting HSD3B1(1245C).

### Claim 19 (depends on 14)

The kit of claim 14, wherein the steroid-dependent disease is prostate cancer.
